| Cohort | First Dose | Second Dose | Third dose | Booster |
Over 18 | - Age 40 and over - Health social care staff - carers of elderly/disabled person - age 18 and over living with immunosuppressed - person age 18-64 in at risk group (4-week deferral after Covid +ve) | Pfizer or Moderna AZ suitable for those 40+ only | Same vaccine as first dose, 8-week interval | Not unless contacted by specialist or GP practice | 3 months after 2nd dose, either Pfizer or half-dose Moderna |
Immunosuppressed age 18 and over (4-week deferral after Covid +ve) | Pfizer or Moderna | Same vaccine as first dose, 8-week interval | Pfizer or Moderna. Specialist will contact Pt and advise timing of 3rd dose | 3 months after 3rd dose, either Pfizer or half-dose Moderna |
18-39 not in at risk group (4-week deferral after Covid +ve) | Pfizer or Moderna | Same vaccine as first dose, 8-week interval | Not recommended currently | 3 months after 3rd dose, either Pfizer or half-dose Moderna |
Under 18 | Immunosuppressed age 12-15 (4-week deferral after Covid +ve) | Pfizer 30 microgram | Pfizer, 8-week interval | Pfizer. Specialist will contact Pt and advise timing of 3rd dose | 3 months after 3rd dose, Pfizer |
Immunosuppressed age 16-17 (4-week deferral after Covid +ve) | Pfizer 30 microgram | Pfizer, 8-week interval | Pfizer. Specialist will contact Pt and advise timing of 3rd dose | 3 months after 3rd dose, Pfizer |
12–15-year-olds in at risk group- table 4 Green book chapter 14a, including contacts of immunosuppressed person (4-week deferral after Covid +ve) | Pfizer 30 microgram | Pfizer, 8-week interval | Not recommended currently | 3 months after 2nd dose, Pfizer |
Age 16-17 at in an at risk group (table 3 Greenbook) (4-week deferral after Covid +ve) | Pfizer 30 microgram | Pfizer, 8-week interval | Not recommended currently | 3 months after 2nd dose, Pfizer |
Age 12–15 not in higher risk group (12-week deferral after Covid +ve) | Pfizer 30 microgram | Pfizer, 12-week interval | Not recommended currently | Not recommended currently |
Age 16-17 not in higher risk group (12-week deferral after Covid +ve) | Pfizer 30 microgram | Pfizer, 12-week interval | Not recommended currently | 3 months after 2nd dose, Pfizer |
| Immunosuppressed age 5-11 | Pfizer 10 microgram | Pfizer, 8 week interval | Still in development | Still in development |
| Age 5-11 in a clinical risk group, or household contact of immunocompromised (4-week deferral after Covid +ve) | Pfizer 10 microgram | Pfizer, 8 week interval | Not recommended currently | Not recommended currently |
| Age 5-11 not in a higher risk group | Pfizer 10 microgram WAITING FOR PROTOCOL | Pfizer, 12 week interval WAITING FOR PROTOCOL | Not recommended currently | Not recommended currently |